Ardelyx Past Earnings Performance
Past criteria checks 0/6
Ardelyx has been growing earnings at an average annual rate of 10.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 72.1% per year.
Key information
10.5%
Earnings growth rate
31.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 72.1% |
| Return on equity | -45.9% |
| Net Margin | -28.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ardelyx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 252 | -73 | 230 | 0 |
| 30 Jun 24 | 210 | -65 | 198 | 0 |
| 31 Mar 24 | 159 | -66 | 161 | 0 |
| 31 Dec 23 | 124 | -66 | 134 | 0 |
| 30 Sep 23 | 134 | -27 | 106 | 0 |
| 30 Jun 23 | 83 | -56 | 92 | 0 |
| 31 Mar 23 | 63 | -66 | 84 | 0 |
| 31 Dec 22 | 52 | -67 | 77 | 0 |
| 30 Sep 22 | 9 | -114 | 75 | 0 |
| 30 Jun 22 | 5 | -135 | 73 | 0 |
| 31 Mar 22 | 4 | -153 | 75 | 0 |
| 31 Dec 21 | 10 | -158 | 69 | 0 |
| 30 Sep 21 | 11 | -151 | 66 | 0 |
| 30 Jun 21 | 12 | -125 | 56 | 0 |
| 31 Mar 21 | 13 | -105 | 43 | 0 |
| 31 Dec 20 | 8 | -94 | 33 | 0 |
| 30 Sep 20 | 8 | -85 | 29 | 0 |
| 30 Jun 20 | 8 | -91 | 28 | 0 |
| 31 Mar 20 | 6 | -91 | 26 | 0 |
| 31 Dec 19 | 5 | -95 | 24 | 0 |
| 30 Sep 19 | 3 | -103 | 23 | 22 |
| 30 Jun 19 | 0 | -104 | 22 | 40 |
| 31 Mar 19 | 0 | -100 | 23 | 56 |
| 31 Dec 18 | 3 | -91 | 24 | 0 |
| 30 Sep 18 | 45 | -53 | 24 | 64 |
| 30 Jun 18 | 44 | -50 | 24 | 62 |
| 31 Mar 18 | 44 | -53 | 23 | 66 |
| 31 Dec 17 | 42 | -64 | 23 | 75 |
| 30 Sep 17 | 0 | -106 | 23 | 150 |
| 30 Jun 17 | 0 | -114 | 21 | 134 |
| 31 Mar 17 | 0 | -117 | 21 | 114 |
| 31 Dec 16 | 0 | -112 | 19 | 94 |
| 30 Sep 16 | 0 | -98 | 18 | 0 |
| 30 Jun 16 | 0 | -87 | 17 | 0 |
| 31 Mar 16 | 18 | -50 | 15 | 0 |
| 31 Dec 15 | 24 | -30 | 14 | 39 |
| 30 Sep 15 | 30 | -16 | 12 | 0 |
| 30 Jun 15 | 38 | 2 | 11 | 0 |
| 31 Mar 15 | 29 | -6 | 9 | 0 |
| 31 Dec 14 | 32 | -3 | 7 | 0 |
| 30 Sep 14 | 34 | -4 | 6 | 1 |
| 30 Jun 14 | 33 | -5 | 5 | 3 |
| 31 Mar 14 | 31 | -7 | 5 | 6 |
| 31 Dec 13 | 29 | -7 | 4 | 0 |
Quality Earnings: 41X is currently unprofitable.
Growing Profit Margin: 41X is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 41X is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.
Accelerating Growth: Unable to compare 41X's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 41X is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: 41X has a negative Return on Equity (-45.85%), as it is currently unprofitable.